Lv53
936 积分 2026-02-25 加入
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
4天前
已完结
64 Cu-Labeled Stapled Peptide-Based Radiopharmaceuticals Targeting MDM2/MDMX for Pan-p53 Tumors
3个月前
已完结
Precise PEGylation Modulates the in Vivo Fate of Peptide Radiopharmaceuticals
3个月前
已完结
EP.13.29 Safety and Efficacy of DLL3 CAR-T Cells Armored With dnTGFBR2 in a Patient With Recurrent Small-Cell Lung Cancer
3个月前
已关闭
Covalent targeted radioligands potentiate radionuclide therapy
3个月前
已完结
Synergistic Enhancement of Catalytic Activities in Ligand‐Regulated Carbon Dots‐Ferric Ion Nanozymes via UV‐Enhanced Peroxidase‐Oxidase
5个月前
已完结
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent
5个月前
已完结
Inflammasome components as new therapeutic targets in inflammatory disease
6个月前
已完结
Drug in Drug: A Host–Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti‐Inflammation
6个月前
已完结
Therapeutic potential of targeting macrophages and microglia in glioblastoma
7个月前
已完结
皖公网安备34019202002308
